Compare Abbott Laboratories (ABT) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Alliant Energy Corporation — how do they compare? Abbott Laboratories trades at $110.72 (market cap $187.95B), while Alliant Energy Corporation trades at $70.26 (market cap $17.78B). The key difference: Abbott Laboratories is far larger — about 10.6× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.12%). Which is the better fit depends on your goals.
| ABT | LNT | |
|---|---|---|
Market Cap | $187.95B | $17.78B |
Sector | Health | Utilities |
52-Week High | $136.62 | $78.03 |
52-Week Low | $82.57 | $63.62 |
Enterprise Value | $214.96B | $29.88B |
Dividend Yield | 2.32% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Alliant Energy (LNT) trades at $70.01, up 2.64% today. The stock shows a bearish technical trend with support at $67-$68 and resistance at $69-$70. Fundamentally, the company reported strong Q2 2026 earnings of $0.65 per share, beating estimates, and maintains solid profitability with an 18.45% net income margin. Analyst consensus is a 'Buy' with a $77.67 price target, implying 11% upside. Recent news highlights institutional buying and dividend stability.
LNT offers a stable investment with consistent earnings growth and a reliable dividend, but faces risks from rising debt levels and regulatory pressures. The stock's current valuation at a P/E of 21.7 is reasonable for a utility, supporting a cautious bullish outlook amid technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
